FDA lifts hold on Concert Pharma's hair loss drug

July 10 (Reuters) - Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration lifted the clinical hold on a mid-stage study testing its drug to treat alopecia areata, a type of hair loss.

The company, which will resume enrollment later this month, expects to complete the study in the second half of 2018. (Reporting by Divya Grover in Bengaluru; Edited by Martina D'Couto)